Effects of growth hormone (GH) administration on functional hepatic nitrogen clearance: studies in normal subjects and GH-deficient patients.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A decline in serum urea levels and urinary urea excretion is usually seen after GH administration in humans, indicating overall protein anabolism.

Whether this reflects the diminished supply of alpha-amino acids for urea synthesis or a substrate-independent hepatic mechanism is unknown.

Who Took Part

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

A decline in serum urea levels and urinary urea excretion is usually seen after GH administration in humans, indicating overall protein anabolism.

The slope of the linear relationship between UNSR and circulating alanine levels represents the hepatic components of conversion of amino nitrogen and is denoted the functional hepatic nitrogen clearance (FHNC).

The subject headings attached to it are Carrier Proteins, Growth Hormone, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor I, Liver, Metabolic Clearance Rate and Nitrogen.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1994 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.